A phase 1 study of heat/phenol‐killed, E. coli‐encapsulated, recombinant modified peanut proteins Ara h 1, Ara h 2, and Ara h 3 (EMP‐123) for the treatment of peanut allergy

ConclusionsRectal administration of EMP‐123 resulted in frequent adverse reactions, including severe allergic reactions in 20%.

Source: Allergy - April 29, 2013 Category: Allergy & Immunology Authors: R. A. Wood, S. H. Sicherer, A. W. Burks, A. Grishin, A. K. Henning, R. Lindblad, D. Stablein, H. A. Sampson Tags: Original Article Source Type: research